{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1649413.714","value":"1811283.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"title":"In CR/sCR at 6 mth"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6810471.278","value":"1156887.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"title":"Not in CR/sCR at 6 mth"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4757894.776","value":"1811283.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"title":"In CR/sCR at 12 mth"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1535876.342","value":"1019484.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Not in CR/sCR at 12 mth"}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"Quantitation of CAR T-cells in peripheral blood will be determined at specified timepoints by quantitative PCR assay, measured in copies/mcg genomic DNA. Persistence will be measured in 2 ways: 1) as an area under the curve (AUC) over first 6 months post CAR T-cell infusion; and 2) as still having detectable CAR T-cells at 6 months post CAR T-cell infusion. AUC6mos and 6-month persistence will be compared between subjects who are and are not in CR at 6 months and 12 months.","dispersionType":"Standard Deviation","groups":[{"description":"Patients complete apheresis and proceed to lymphodepleting chemotherapy with cyclophosphamide 300mg/m\\^2 and fludarabine 30mg/m\\^2 for 3 consecutive days followed by the infusion of BCMA CAR T-cells at a target dose of 450 x10\\^6 cells. Maintenance lenalidomide, starting at 5mg a day for 21 days of a 28-day cycle will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the patient reaches 12 months post CAR T-cell infusion and continue free of progression.\n\nLenalidomide: Maintenance lenalidomide, starting at 5 mg a day for 21 days of a 28-day cycle, will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the participant reaches 12 months post CAR T-cell infusion and continues free of progression\n\nbb2121: Participants receive infusion of BCMA CAR T-cells at a target dose of 450 x 10\\^6 cells.\n\nCyclophosphamide: 300 mg/m\\^2/day for 3 consecutive days prior to the CAR T infusion\n\nFludarabine: 30 mg/m\\^2/day or 3 consecutive days prior to the CAR T infusion\n\nleukapheresis: Placement of central line catheter and leukapheresis","id":"OG000","title":"Lenalidomide and bb2121"}],"paramType":"MEDIAN","populationDescription":"Participants who received and infusion","reportingStatus":"POSTED","timeFrame":"6 months, 1 Year","title":"Exploratory Objective 2: CAR T-cell Persistence Area Under the Curve Over the First 6 Months Post CAR T-cell Infusion","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"months*(copies/mcg of DNA)"}